4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $300 | $793 | $719 | $608 |
| - Cash | $149 | $249 | $219 | $153 |
| + Debt | $25 | $15 | $16 | $16 |
| Enterprise Value | $176 | $558 | $516 | $472 |
| Revenue | $0 | $21 | $3 | $18 |
| % Growth | -99.8% | 562.3% | -82.7% | – |
| Gross Profit | $0 | -$76 | -$77 | -$43 |
| % Margin | 100% | -368.5% | -2,464.8% | -240.2% |
| EBITDA | -$181 | -$109 | -$108 | -$70 |
| % Margin | -489,556.8% | -524.4% | -3,439.7% | -387% |
| Net Income | -$161 | -$101 | -$107 | -$71 |
| % Margin | -434,778.4% | -486.6% | -3,435.4% | -395.4% |
| EPS Diluted | -2.98 | -2.58 | -3.12 | -2.46 |
| % Growth | -15.5% | 17.3% | -26.8% | – |
| Operating Cash Flow | -$135 | -$76 | -$87 | -$69 |
| Capital Expenditures | -$4 | -$3 | -$12 | -$9 |
| Free Cash Flow | -$138 | -$79 | -$98 | -$78 |